Blood cancers

New drugs for blood cancers get approval for PBS listing

The Pharmaceutical Benefits Advisory Committee (PBAC) has approved a PBS listing for ralatrexate (Folotyn) for the treatment of Peripheral T-Cell Lymphoma. At its November 2017 meeting the PBAC supported a request from MundiPharma for a Section 100 listing for the treatment of patients who are refractory to, or have relapsed following, first line chemotherapy. The ...

Already a member?

Login to keep reading.

© 2021 the limbic